ZA200507158B - Treatment of incontinence with 5HTC2 agonists - Google Patents
Treatment of incontinence with 5HTC2 agonists Download PDFInfo
- Publication number
- ZA200507158B ZA200507158B ZA200507158A ZA200507158A ZA200507158B ZA 200507158 B ZA200507158 B ZA 200507158B ZA 200507158 A ZA200507158 A ZA 200507158A ZA 200507158 A ZA200507158 A ZA 200507158A ZA 200507158 B ZA200507158 B ZA 200507158B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- alkyl
- tetrahydro
- hydrogen
- alkoxy
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title claims description 40
- 206010021639 Incontinence Diseases 0.000 title claims description 39
- 238000011282 treatment Methods 0.000 title claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 159
- 239000001257 hydrogen Substances 0.000 claims description 107
- 229910052739 hydrogen Inorganic materials 0.000 claims description 107
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 claims description 78
- 125000000217 alkyl group Chemical group 0.000 claims description 69
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 claims description 68
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 63
- -1 oxy, thio, amino Chemical group 0.000 claims description 57
- 229910052736 halogen Inorganic materials 0.000 claims description 54
- 230000000694 effects Effects 0.000 claims description 44
- 239000000018 receptor agonist Substances 0.000 claims description 40
- 229940044601 receptor agonist Drugs 0.000 claims description 40
- 150000002367 halogens Chemical class 0.000 claims description 37
- 150000002431 hydrogen Chemical group 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 37
- 125000003545 alkoxy group Chemical group 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 31
- 229920006395 saturated elastomer Polymers 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 25
- 230000004044 response Effects 0.000 claims description 24
- 125000003282 alkyl amino group Chemical group 0.000 claims description 23
- 238000012360 testing method Methods 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 125000005843 halogen group Chemical group 0.000 claims description 21
- 229910052791 calcium Inorganic materials 0.000 claims description 19
- 238000003556 assay Methods 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 101150013372 Htr2c gene Proteins 0.000 claims description 10
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical group ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 9
- 206010053236 Mixed incontinence Diseases 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- QZYYPQAYSFBKPW-UHFFFAOYSA-N org 12962 Chemical compound N1=C(Cl)C(C(F)(F)F)=CC=C1N1CCNCC1 QZYYPQAYSFBKPW-UHFFFAOYSA-N 0.000 claims description 8
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 claims description 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 4
- 125000004532 benzofuran-3-yl group Chemical group O1C=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims description 4
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims description 4
- 125000004551 isoquinolin-3-yl group Chemical group C1=NC(=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims description 4
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 claims description 4
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 claims description 4
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims description 4
- 230000000638 stimulation Effects 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 4
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 claims description 3
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- PHGWDAICBXUJDU-UHFFFAOYSA-N 8,9-dichloro-1,2,3,4,4a,6-hexahydropyrazino[1,2-a]quinoxalin-5-one Chemical compound N1C(=O)C2CNCCN2C2=C1C=C(Cl)C(Cl)=C2 PHGWDAICBXUJDU-UHFFFAOYSA-N 0.000 claims description 3
- 238000000670 ligand binding assay Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 125000004512 1,2,3-thiadiazol-4-yl group Chemical group S1N=NC(=C1)* 0.000 claims description 2
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 claims description 2
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 claims description 2
- 125000004510 1,3,4-oxadiazol-5-yl group Chemical group O1C=NN=C1* 0.000 claims description 2
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 claims description 2
- 125000004522 1,3,4-thiadiazol-5-yl group Chemical group S1C=NN=C1* 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 48
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 239000000651 prodrug Substances 0.000 claims 12
- 229940002612 prodrug Drugs 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 241000080590 Niso Species 0.000 claims 1
- 239000011575 calcium Substances 0.000 description 48
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 41
- 210000003932 urinary bladder Anatomy 0.000 description 34
- 229940079593 drug Drugs 0.000 description 21
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 19
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 18
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 230000027939 micturition Effects 0.000 description 16
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 15
- 238000011049 filling Methods 0.000 description 14
- GRFOHUBBUMAJMM-UHFFFAOYSA-N 3-(2-aminoquinolin-3-yl)-n-cyclohexyl-n-methylpropanamide Chemical compound C=1C2=CC=CC=C2N=C(N)C=1CCC(=O)N(C)C1CCCCC1 GRFOHUBBUMAJMM-UHFFFAOYSA-N 0.000 description 12
- 210000002700 urine Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000003187 abdominal effect Effects 0.000 description 10
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 8
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 8
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 8
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 238000002825 functional assay Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 230000036515 potency Effects 0.000 description 7
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- BRKIIHVUPRCOBS-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound FC1=CC=CC(COC=2N=C(C=CN=2)N2CCNCC2)=C1F BRKIIHVUPRCOBS-UHFFFAOYSA-N 0.000 description 5
- XRDLYGQZGDDPDQ-UHFFFAOYSA-N 2-[(2,5-difluorophenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound FC1=CC=C(F)C(COC=2N=C(C=CN=2)N2CCNCC2)=C1 XRDLYGQZGDDPDQ-UHFFFAOYSA-N 0.000 description 5
- PNURVKWAXKYLMY-UHFFFAOYSA-N 2-[(3,5-dichlorophenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound ClC1=CC(Cl)=CC(COC=2N=C(C=CN=2)N2CCNCC2)=C1 PNURVKWAXKYLMY-UHFFFAOYSA-N 0.000 description 5
- KTQUGATZSUAOQS-GFCCVEGCSA-N 2-[(3-chlorophenyl)methoxy]-4-[(2r)-2-methylpiperazin-1-yl]pyrimidine Chemical compound C[C@@H]1CNCCN1C1=CC=NC(OCC=2C=C(Cl)C=CC=2)=N1 KTQUGATZSUAOQS-GFCCVEGCSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- KCLCKODCAVJSID-ZCFIWIBFSA-N (2r)-2-ethylpiperazine-1-carboxylic acid Chemical compound CC[C@@H]1CNCCN1C(O)=O KCLCKODCAVJSID-ZCFIWIBFSA-N 0.000 description 4
- BQYVCCOLZOZOFW-LLVKDONJSA-N 2-[(2,5-difluorophenyl)methoxy]-4-[(2r)-2-methylpiperazin-1-yl]pyrimidine Chemical compound C[C@@H]1CNCCN1C1=CC=NC(OCC=2C(=CC=C(F)C=2)F)=N1 BQYVCCOLZOZOFW-LLVKDONJSA-N 0.000 description 4
- FPPQVDJKEFJQSA-UHFFFAOYSA-N 2-[(3,5-difluorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group FC1=CC(F)=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1 FPPQVDJKEFJQSA-UHFFFAOYSA-N 0.000 description 4
- UDITUSZOFDATJR-UHFFFAOYSA-N 2-[(3-chlorophenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound ClC1=CC=CC(COC=2N=C(C=CN=2)N2CCNCC2)=C1 UDITUSZOFDATJR-UHFFFAOYSA-N 0.000 description 4
- 108060003345 Adrenergic Receptor Proteins 0.000 description 4
- 102000017910 Adrenergic receptor Human genes 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000036724 intravesical pressure Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- QIRJIVPBWTXCEE-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-4-piperazin-1-ylpyrimidin-2-amine Chemical compound ClC1=CC=CC(CNC=2N=C(C=CN=2)N2CCNCC2)=C1 QIRJIVPBWTXCEE-UHFFFAOYSA-N 0.000 description 4
- XIGCMLQZNVYBFC-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-2-piperazin-1-ylpyrimidin-4-amine Chemical compound FC1=CC=CC(CNC=2N=C(N=CC=2)N2CCNCC2)=C1 XIGCMLQZNVYBFC-UHFFFAOYSA-N 0.000 description 4
- VOARFYJOUYYBBO-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-4-piperazin-1-ylpyrimidin-2-amine Chemical compound FC1=CC=CC(CNC=2N=C(C=CN=2)N2CCNCC2)=C1 VOARFYJOUYYBBO-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000005070 sphincter Anatomy 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
- ALWQBVRXXALOIX-UHFFFAOYSA-N 2-[(2-chlorophenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound ClC1=CC=CC=C1COC1=NC=CC(N2CCNCC2)=N1 ALWQBVRXXALOIX-UHFFFAOYSA-N 0.000 description 3
- RWFXQDJYNCYBMZ-GFCCVEGCSA-N 2-[(3-chlorophenyl)methoxy]-6-[(2r)-2-methylpiperazin-1-yl]pyrazine Chemical group C[C@@H]1CNCCN1C1=CN=CC(OCC=2C=C(Cl)C=CC=2)=N1 RWFXQDJYNCYBMZ-GFCCVEGCSA-N 0.000 description 3
- PCWGGOVOEWHPMG-UHFFFAOYSA-N 2-[(3-chlorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group ClC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1 PCWGGOVOEWHPMG-UHFFFAOYSA-N 0.000 description 3
- USDZQWDVSSESIH-UHFFFAOYSA-N 2-[(3-fluorophenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound FC1=CC=CC(COC=2N=C(C=CN=2)N2CCNCC2)=C1 USDZQWDVSSESIH-UHFFFAOYSA-N 0.000 description 3
- KATOHVKJXICHEN-UHFFFAOYSA-N 2-[(3-fluorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group FC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1 KATOHVKJXICHEN-UHFFFAOYSA-N 0.000 description 3
- OMMBWIWJPLKNFD-UHFFFAOYSA-N 2-phenylmethoxy-6-piperazin-1-ylpyrazine Chemical group C=1C=CC=CC=1COC(N=1)=CN=CC=1N1CCNCC1 OMMBWIWJPLKNFD-UHFFFAOYSA-N 0.000 description 3
- ZZGXJWPNJUVOCQ-UHFFFAOYSA-N 4-phenylmethoxy-2-piperazin-1-ylpyrimidine Chemical compound C=1C=CC=CC=1COC(N=1)=CC=NC=1N1CCNCC1 ZZGXJWPNJUVOCQ-UHFFFAOYSA-N 0.000 description 3
- BKZIGBBKEASYTN-UHFFFAOYSA-N 4-piperazin-1-yl-2-[(2,3,5-trifluorophenyl)methoxy]pyrimidine Chemical compound FC1=CC(F)=C(F)C(COC=2N=C(C=CN=2)N2CCNCC2)=C1 BKZIGBBKEASYTN-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 3
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 3
- 101000761348 Homo sapiens 5-hydroxytryptamine receptor 2C Proteins 0.000 description 3
- 206010046543 Urinary incontinence Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 102000045993 human HTR2C Human genes 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- GWGJQKSPIFQZSN-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-2-piperazin-1-ylpyrimidin-4-amine Chemical compound ClC1=CC=CC(CNC=2N=C(N=CC=2)N2CCNCC2)=C1 GWGJQKSPIFQZSN-UHFFFAOYSA-N 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 3
- 239000002484 serotonin 2C antagonist Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 210000003699 striated muscle Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- MRXGFASLDAZMJE-LLVKDONJSA-N 2-[(2,5-dichlorophenyl)methoxy]-4-[(2r)-2-methylpiperazin-1-yl]pyrimidine Chemical compound C[C@@H]1CNCCN1C1=CC=NC(OCC=2C(=CC=C(Cl)C=2)Cl)=N1 MRXGFASLDAZMJE-LLVKDONJSA-N 0.000 description 2
- TZZAFXPZDBVHGJ-UHFFFAOYSA-N 2-[(2,5-dichlorophenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound ClC1=CC=C(Cl)C(COC=2N=C(C=CN=2)N2CCNCC2)=C1 TZZAFXPZDBVHGJ-UHFFFAOYSA-N 0.000 description 2
- SNWOBEHYYUYURQ-UHFFFAOYSA-N 2-[(2,5-dichlorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group ClC1=CC=C(Cl)C(COC=2N=C(C=NC=2)N2CCNCC2)=C1 SNWOBEHYYUYURQ-UHFFFAOYSA-N 0.000 description 2
- KFSIBDILKOCDLE-UHFFFAOYSA-N 2-[(2-fluorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group FC1=CC=CC=C1COC1=CN=CC(N2CCNCC2)=N1 KFSIBDILKOCDLE-UHFFFAOYSA-N 0.000 description 2
- VSMKYRFYLHYLFY-UHFFFAOYSA-N 2-[(3-chlorophenyl)methylsulfanyl]-6-piperazin-1-ylpyrazine Chemical group ClC1=CC=CC(CSC=2N=C(C=NC=2)N2CCNCC2)=C1 VSMKYRFYLHYLFY-UHFFFAOYSA-N 0.000 description 2
- COQKRZUTHFXRJV-UHFFFAOYSA-N 2-[(3-methoxyphenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound COC1=CC=CC(COC=2N=C(C=CN=2)N2CCNCC2)=C1 COQKRZUTHFXRJV-UHFFFAOYSA-N 0.000 description 2
- AVIQWPWNFJDNIP-UHFFFAOYSA-N 2-[(6-chloropyridin-2-yl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound ClC1=CC=CC(COC=2N=C(C=CN=2)N2CCNCC2)=N1 AVIQWPWNFJDNIP-UHFFFAOYSA-N 0.000 description 2
- WMZHFOOIFQPPDL-UHFFFAOYSA-N 2-[(6-methylpyridin-2-yl)methoxy]-6-piperazin-1-ylpyrazine Chemical group CC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=N1 WMZHFOOIFQPPDL-UHFFFAOYSA-N 0.000 description 2
- KPBGYRGQZIDMFT-UHFFFAOYSA-N 2-benzylsulfanyl-6-piperazin-1-ylpyrazine Chemical group C=1C=CC=CC=1CSC(N=1)=CN=CC=1N1CCNCC1 KPBGYRGQZIDMFT-UHFFFAOYSA-N 0.000 description 2
- WEFWVXXUGIKYLH-UHFFFAOYSA-N 2-phenylmethoxy-4-piperazin-1-ylpyrimidine Chemical compound C=1C=CC=CC=1COC(N=1)=NC=CC=1N1CCNCC1 WEFWVXXUGIKYLH-UHFFFAOYSA-N 0.000 description 2
- BTFBHHWABYOSPA-UHFFFAOYSA-N 3-[[(6-piperazin-1-ylpyrazin-2-yl)amino]methyl]benzonitrile Chemical compound N#CC1=CC=CC(CNC=2N=C(C=NC=2)N2CCNCC2)=C1 BTFBHHWABYOSPA-UHFFFAOYSA-N 0.000 description 2
- LIRBEKSOJXQCQB-UHFFFAOYSA-N 4-methyl-2-phenylmethoxy-6-piperazin-1-ylpyrimidine Chemical compound N=1C(C)=CC(N2CCNCC2)=NC=1OCC1=CC=CC=C1 LIRBEKSOJXQCQB-UHFFFAOYSA-N 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108010001441 Phosphopeptides Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 201000003892 detrusor sphincter dyssynergia Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- FYWOHRYTOCDGHZ-UHFFFAOYSA-N n-[(3,5-dichlorophenyl)methyl]-6-piperazin-1-ylpyrazin-2-amine Chemical compound ClC1=CC(Cl)=CC(CNC=2N=C(C=NC=2)N2CCNCC2)=C1 FYWOHRYTOCDGHZ-UHFFFAOYSA-N 0.000 description 2
- DIERXLYMJQVEND-UHFFFAOYSA-N n-[(3,5-difluorophenyl)methyl]-6-piperazin-1-ylpyrazin-2-amine Chemical compound FC1=CC(F)=CC(CNC=2N=C(C=NC=2)N2CCNCC2)=C1 DIERXLYMJQVEND-UHFFFAOYSA-N 0.000 description 2
- VQMSZKDMVHWVFM-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-6-(2-methylpiperazin-1-yl)pyrazin-2-amine Chemical compound CC1CNCCN1C1=CN=CC(NCC=2C=C(Cl)C=CC=2)=N1 VQMSZKDMVHWVFM-UHFFFAOYSA-N 0.000 description 2
- PXXBUFCUGLZABH-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-n-(6-piperazin-1-ylpyrazin-2-yl)acetamide Chemical compound C=1N=CC(N2CCNCC2)=NC=1N(C(=O)C)CC1=CC=CC(Cl)=C1 PXXBUFCUGLZABH-UHFFFAOYSA-N 0.000 description 2
- XYISMKOEWXHJEE-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-6-piperazin-1-ylpyrazin-2-amine Chemical compound FC1=CC=CC(CNC=2N=C(C=NC=2)N2CCNCC2)=C1 XYISMKOEWXHJEE-UHFFFAOYSA-N 0.000 description 2
- UCTDIIVSAPSFRV-UHFFFAOYSA-N n-benzyl-2-piperazin-1-ylpyrimidin-4-amine Chemical compound C=1C=CC=CC=1CNC(N=1)=CC=NC=1N1CCNCC1 UCTDIIVSAPSFRV-UHFFFAOYSA-N 0.000 description 2
- SGUBXKWIXLLZPM-UHFFFAOYSA-N n-benzyl-4-piperazin-1-ylpyrimidin-2-amine Chemical compound C=1C=CC=CC=1CNC(N=1)=NC=CC=1N1CCNCC1 SGUBXKWIXLLZPM-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000002485 serotonin 2C agonist Substances 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 206010041232 sneezing Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- GFDFZTFQPIBNSQ-UHFFFAOYSA-N (+)-homo-18-epiormosanine Natural products C1C(C23)CCCN3CN3CCCCC3C32CN2CCCCC2C1C3 GFDFZTFQPIBNSQ-UHFFFAOYSA-N 0.000 description 1
- KALDYHARSPUPKC-GFCCVEGCSA-N (2,6-difluoro-4-prop-2-ynoxyphenyl)methyl (2r)-2-ethylpiperazine-1-carboxylate Chemical compound CC[C@@H]1CNCCN1C(=O)OCC1=C(F)C=C(OCC#C)C=C1F KALDYHARSPUPKC-GFCCVEGCSA-N 0.000 description 1
- OTZUXDKPQPFVDM-GFCCVEGCSA-N (2-chloro-6-fluoro-4-prop-2-ynoxyphenyl)methyl (2r)-2-ethylpiperazine-1-carboxylate Chemical compound CC[C@@H]1CNCCN1C(=O)OCC1=C(F)C=C(OCC#C)C=C1Cl OTZUXDKPQPFVDM-GFCCVEGCSA-N 0.000 description 1
- RUCPUQIUIHZKIW-GFCCVEGCSA-N (2-chloro-6-fluoro-4-propoxyphenyl)methyl (2r)-2-ethylpiperazine-1-carboxylate Chemical compound ClC1=CC(OCCC)=CC(F)=C1COC(=O)N1[C@H](CC)CNCC1 RUCPUQIUIHZKIW-GFCCVEGCSA-N 0.000 description 1
- XFWLERLAWZDCRZ-CQSZACIVSA-N (2-fluoro-5-pentoxyphenyl)methyl (2r)-2-methylpiperazine-1-carboxylate Chemical compound CCCCCOC1=CC=C(F)C(COC(=O)N2[C@@H](CNCC2)C)=C1 XFWLERLAWZDCRZ-CQSZACIVSA-N 0.000 description 1
- MLBHFBKZUPLWBD-ZETCQYMHSA-N (2S)-1-[3-(trifluoromethyl)phenyl]-2-propanamine Chemical compound C[C@H](N)CC1=CC=CC(C(F)(F)F)=C1 MLBHFBKZUPLWBD-ZETCQYMHSA-N 0.000 description 1
- PRWOYVUMSZQUCT-OAHLLOKOSA-N (2r)-2-[[4-(difluoromethoxy)phenyl]methyl]-2-ethylpiperazine-1-carboxylic acid Chemical compound C=1C=C(OC(F)F)C=CC=1C[C@]1(CC)CNCCN1C(O)=O PRWOYVUMSZQUCT-OAHLLOKOSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OBQZQQHWYDPMDY-VIFPVBQESA-N (2s)-1-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)propan-2-amine Chemical compound C1=C2OCCC2=C2N(C[C@@H](N)C)CCC2=C1 OBQZQQHWYDPMDY-VIFPVBQESA-N 0.000 description 1
- UTLBGXQIQOXKNB-VIFPVBQESA-N (2s)-1-(7,8-dihydro-6h-pyrido[4,3-b]pyrrolizin-5-yl)propan-2-amine Chemical compound C12=CN=CC=C2C(C[C@@H](N)C)=C2N1CCC2 UTLBGXQIQOXKNB-VIFPVBQESA-N 0.000 description 1
- JYSVKYGPBNOLPK-VIFPVBQESA-N (2s)-1-(7-fluoro-8-methoxy-2,3-dihydro-1h-cyclopenta[b]indol-4-yl)propan-2-amine Chemical compound COC1=C(F)C=CC2=C1C(CCC1)=C1N2C[C@H](C)N JYSVKYGPBNOLPK-VIFPVBQESA-N 0.000 description 1
- TZKHUTNZGIQFHG-QMMMGPOBSA-N (2s)-1-(7-methoxythieno[2,3-g]indazol-1-yl)propan-2-amine Chemical compound S1C(OC)=CC2=C1C=CC1=C2N(C[C@H](C)N)N=C1 TZKHUTNZGIQFHG-QMMMGPOBSA-N 0.000 description 1
- PHGWDAICBXUJDU-SNVBAGLBSA-N (4ar)-8,9-dichloro-1,2,3,4,4a,6-hexahydropyrazino[1,2-a]quinoxalin-5-one Chemical compound C([C@@H]1C(=O)N2)NCCN1C1=C2C=C(Cl)C(Cl)=C1 PHGWDAICBXUJDU-SNVBAGLBSA-N 0.000 description 1
- HAZWRUAJTCVCEE-MRVPVSSYSA-N (4r)-4-methyl-6-(trifluoromethyl)-1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical compound C1=CC(C(F)(F)F)=C2N3[C@H](C)CNCC3=CC2=C1 HAZWRUAJTCVCEE-MRVPVSSYSA-N 0.000 description 1
- FVONZVAYLZSBOJ-SECBINFHSA-N (4r)-6-ethyl-8-fluoro-4-methyl-1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical compound C1=C2CNC[C@@H](C)N2C2=C1C=C(F)C=C2CC FVONZVAYLZSBOJ-SECBINFHSA-N 0.000 description 1
- QCCLCOBTVCROQM-MRVPVSSYSA-N (4r)-7-chloro-4-methyl-1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical compound C1=C(Cl)C=C2N3[C@H](C)CNCC3=CC2=C1 QCCLCOBTVCROQM-MRVPVSSYSA-N 0.000 description 1
- PLPARSCPGGUWDI-SECBINFHSA-N (4r)-8-fluoro-4,7-dimethyl-1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical compound FC1=C(C)C=C2N3[C@H](C)CNCC3=CC2=C1 PLPARSCPGGUWDI-SECBINFHSA-N 0.000 description 1
- RXFLPRDWCDWXHV-FUTAKVPZSA-N (e)-n,n-dimethyl-3-[3-[2-[3-[(2r)-2-methylpiperazin-1-yl]pyrazin-2-yl]oxyethoxy]pyridin-2-yl]prop-2-en-1-amine Chemical compound C[C@@H]1CNCCN1C1=NC=CN=C1OCCOC1=CC=CN=C1\C=C\CN(C)C RXFLPRDWCDWXHV-FUTAKVPZSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 description 1
- ASYRZEICFCXPBF-UHFFFAOYSA-N 1-(5,6-difluoro-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound FC1=C(F)C=C2N(CC(N)C)CCC2=C1 ASYRZEICFCXPBF-UHFFFAOYSA-N 0.000 description 1
- DRLGTCNDEBEPQP-UHFFFAOYSA-N 1-(5,6-difluoro-3-methylindazol-1-yl)propan-2-amine Chemical compound FC1=C(F)C=C2N(CC(N)C)N=C(C)C2=C1 DRLGTCNDEBEPQP-UHFFFAOYSA-N 0.000 description 1
- SGEUVUWZSAXGFY-UHFFFAOYSA-N 1-(5-bromo-2h-indazol-3-yl)propan-2-amine Chemical compound C1=C(Br)C=C2C(CC(N)C)=NNC2=C1 SGEUVUWZSAXGFY-UHFFFAOYSA-N 0.000 description 1
- CFOYPOXDKROVPX-UHFFFAOYSA-N 1-(5-chloro-1-methylindazol-3-yl)propan-2-amine Chemical compound C1=C(Cl)C=C2C(CC(N)C)=NN(C)C2=C1 CFOYPOXDKROVPX-UHFFFAOYSA-N 0.000 description 1
- SBKWOWHPSMTOBC-UHFFFAOYSA-N 1-(5-chloro-1-propan-2-ylindazol-3-yl)propan-2-amine Chemical compound C1=C(Cl)C=C2C(CC(N)C)=NN(C(C)C)C2=C1 SBKWOWHPSMTOBC-UHFFFAOYSA-N 0.000 description 1
- HFVVDQSCZPXWSY-UHFFFAOYSA-N 1-(5-chloro-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound ClC1=CC=C2N(CC(N)C)CCC2=C1 HFVVDQSCZPXWSY-UHFFFAOYSA-N 0.000 description 1
- RIGRKJDNTIKRQD-UHFFFAOYSA-N 1-(5-chloro-2h-indazol-3-yl)propan-2-amine Chemical compound C1=C(Cl)C=C2C(CC(N)C)=NNC2=C1 RIGRKJDNTIKRQD-UHFFFAOYSA-N 0.000 description 1
- KZFPTLZBQZDFHT-UHFFFAOYSA-N 1-(5-fluoro-6-iodo-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound FC1=C(I)C=C2N(CC(N)C)CCC2=C1 KZFPTLZBQZDFHT-UHFFFAOYSA-N 0.000 description 1
- KATMBNIBQAWHQJ-UHFFFAOYSA-N 1-(5-fluoro-6-methyl-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound FC1=C(C)C=C2N(CC(N)C)CCC2=C1 KATMBNIBQAWHQJ-UHFFFAOYSA-N 0.000 description 1
- IGAAICGMRRWZJW-UHFFFAOYSA-N 1-(5-fluoro-6-methylsulfanyl-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound C1=C(F)C(SC)=CC2=C1CCN2CC(C)N IGAAICGMRRWZJW-UHFFFAOYSA-N 0.000 description 1
- RJYKMNOUJHRYTQ-UHFFFAOYSA-N 1-(5-methoxy-1-methylindazol-3-yl)propan-2-amine Chemical compound COC1=CC=C2N(C)N=C(CC(C)N)C2=C1 RJYKMNOUJHRYTQ-UHFFFAOYSA-N 0.000 description 1
- QGDUUJDJXSDKCP-UHFFFAOYSA-N 1-(6-bromo-3-ethylindazol-1-yl)propan-2-amine Chemical compound BrC1=CC=C2C(CC)=NN(CC(C)N)C2=C1 QGDUUJDJXSDKCP-UHFFFAOYSA-N 0.000 description 1
- XEAADXLKWPGODO-UHFFFAOYSA-N 1-(6-chloro-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound C1=C(Cl)C=C2N(CC(N)C)CCC2=C1 XEAADXLKWPGODO-UHFFFAOYSA-N 0.000 description 1
- OKTLNQVSINRJKA-UHFFFAOYSA-N 1-(6-chloro-5-fluoro-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound FC1=C(Cl)C=C2N(CC(N)C)CCC2=C1 OKTLNQVSINRJKA-UHFFFAOYSA-N 0.000 description 1
- PKGIAAHUVWWFPM-UHFFFAOYSA-N 1-(6-chloro-5-fluoro-3-methylindazol-1-yl)propan-2-amine Chemical compound FC1=C(Cl)C=C2N(CC(N)C)N=C(C)C2=C1 PKGIAAHUVWWFPM-UHFFFAOYSA-N 0.000 description 1
- ZATISPXVUJXJRK-UHFFFAOYSA-N 1-(6-ethylsulfanyl-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound CCSC1=CC=C2CCN(CC(C)N)C2=C1 ZATISPXVUJXJRK-UHFFFAOYSA-N 0.000 description 1
- ALMFEOBYDZUSIC-UHFFFAOYSA-N 1-(6-methoxy-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound COC1=CC=C2CCN(CC(C)N)C2=C1 ALMFEOBYDZUSIC-UHFFFAOYSA-N 0.000 description 1
- WMYZYDUOEKWORM-UHFFFAOYSA-N 1-(6-methoxy-3-methylindazol-1-yl)propan-2-amine Chemical compound COC1=CC=C2C(C)=NN(CC(C)N)C2=C1 WMYZYDUOEKWORM-UHFFFAOYSA-N 0.000 description 1
- MBDXWHFBIOEOHU-UHFFFAOYSA-N 1-(6-methylsulfanyl-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound CSC1=CC=C2CCN(CC(C)N)C2=C1 MBDXWHFBIOEOHU-UHFFFAOYSA-N 0.000 description 1
- SSDXLHXTFQHCNR-UHFFFAOYSA-N 1-(6-propylsulfanyl-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound CCCSC1=CC=C2CCN(CC(C)N)C2=C1 SSDXLHXTFQHCNR-UHFFFAOYSA-N 0.000 description 1
- OCJCKHPFQNWROT-UHFFFAOYSA-N 1-[3-ethyl-6-(trifluoromethyl)indazol-1-yl]propan-2-amine Chemical compound FC(F)(F)C1=CC=C2C(CC)=NN(CC(C)N)C2=C1 OCJCKHPFQNWROT-UHFFFAOYSA-N 0.000 description 1
- HMGZRIYJGAGANE-UHFFFAOYSA-N 1-[5-fluoro-6-(trifluoromethyl)-2,3-dihydroindol-1-yl]propan-2-amine Chemical compound FC1=C(C(F)(F)F)C=C2N(CC(N)C)CCC2=C1 HMGZRIYJGAGANE-UHFFFAOYSA-N 0.000 description 1
- OKHMLNQDEKKFRY-UHFFFAOYSA-N 1-[6-(trifluoromethyl)-2,3-dihydroindol-1-yl]propan-2-amine Chemical compound C1=C(C(F)(F)F)C=C2N(CC(N)C)CCC2=C1 OKHMLNQDEKKFRY-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 1
- DUHRAVUGWQLFKQ-UHFFFAOYSA-N 2-(2-methylpiperazin-1-yl)-6-[(6-methylpyridin-2-yl)methoxy]pyrazine Chemical group CC1CNCCN1C1=CN=CC(OCC=2N=C(C)C=CC=2)=N1 DUHRAVUGWQLFKQ-UHFFFAOYSA-N 0.000 description 1
- LVIRPARUNBTHAR-UHFFFAOYSA-N 2-(6-chloro-2,3-dihydroindol-1-yl)ethanamine Chemical compound C1=C(Cl)C=C2N(CCN)CCC2=C1 LVIRPARUNBTHAR-UHFFFAOYSA-N 0.000 description 1
- RNWQKUXWKDGPTF-UHFFFAOYSA-N 2-[(2,5-difluorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group FC1=CC=C(F)C(COC=2N=C(C=NC=2)N2CCNCC2)=C1 RNWQKUXWKDGPTF-UHFFFAOYSA-N 0.000 description 1
- FUFZPBIDXGUMNR-GFCCVEGCSA-N 2-[(2-chlorophenyl)methoxy]-6-[(2r)-2-methylpiperazin-1-yl]pyrazine Chemical group C[C@@H]1CNCCN1C1=CN=CC(OCC=2C(=CC=CC=2)Cl)=N1 FUFZPBIDXGUMNR-GFCCVEGCSA-N 0.000 description 1
- OOUPQSFTNBGJPD-UHFFFAOYSA-N 2-[(2-chlorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group ClC1=CC=CC=C1COC1=CN=CC(N2CCNCC2)=N1 OOUPQSFTNBGJPD-UHFFFAOYSA-N 0.000 description 1
- FFBVDPBCXIBGLD-UHFFFAOYSA-N 2-[(2-methylphenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group CC1=CC=CC=C1COC1=CN=CC(N2CCNCC2)=N1 FFBVDPBCXIBGLD-UHFFFAOYSA-N 0.000 description 1
- HQRWFZROVHEFSD-UHFFFAOYSA-N 2-[(3,4-difluorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group C1=C(F)C(F)=CC=C1COC1=CN=CC(N2CCNCC2)=N1 HQRWFZROVHEFSD-UHFFFAOYSA-N 0.000 description 1
- USWXRXCXADVWNZ-UHFFFAOYSA-N 2-[(3,5-difluorophenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound FC1=CC(F)=CC(COC=2N=C(C=CN=2)N2CCNCC2)=C1 USWXRXCXADVWNZ-UHFFFAOYSA-N 0.000 description 1
- JPAOODDUOPDRLG-UHFFFAOYSA-N 2-[(3-bromophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group BrC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1 JPAOODDUOPDRLG-UHFFFAOYSA-N 0.000 description 1
- UXNABWNPOYOUBM-GFCCVEGCSA-N 2-[(3-fluorophenyl)methoxy]-6-[(2r)-2-methylpiperazin-1-yl]pyrazine Chemical group C[C@@H]1CNCCN1C1=CN=CC(OCC=2C=C(F)C=CC=2)=N1 UXNABWNPOYOUBM-GFCCVEGCSA-N 0.000 description 1
- FOXDXBPMVWHWLN-UHFFFAOYSA-N 2-[(6-chloropyridin-2-yl)methoxy]-6-piperazin-1-ylpyrazine Chemical group ClC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=N1 FOXDXBPMVWHWLN-UHFFFAOYSA-N 0.000 description 1
- UFRQWANAVAZVHS-UHFFFAOYSA-N 2-[(6-fluoropyridin-2-yl)methoxy]-6-piperazin-1-ylpyrazine Chemical group FC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=N1 UFRQWANAVAZVHS-UHFFFAOYSA-N 0.000 description 1
- WNIDFMGNFAYMIV-UHFFFAOYSA-N 2-[(6-methylpyridin-2-yl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound CC1=CC=CC(COC=2N=C(C=CN=2)N2CCNCC2)=N1 WNIDFMGNFAYMIV-UHFFFAOYSA-N 0.000 description 1
- JMIKUXDRIYZMFK-UHFFFAOYSA-N 2-[1-(2-chlorophenyl)ethoxy]-4-piperazin-1-ylpyrimidine Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(N=1)=NC=CC=1N1CCNCC1 JMIKUXDRIYZMFK-UHFFFAOYSA-N 0.000 description 1
- WUDGUDALTCJVFI-UHFFFAOYSA-N 2-[1-(3-chlorophenyl)ethoxy]-4-methyl-6-piperazin-1-ylpyrimidine Chemical compound C=1C=CC(Cl)=CC=1C(C)OC(N=1)=NC(C)=CC=1N1CCNCC1 WUDGUDALTCJVFI-UHFFFAOYSA-N 0.000 description 1
- PFKJMESILVYLQS-UHFFFAOYSA-N 2-[1-(3-chlorophenyl)ethoxy]-4-piperazin-1-ylpyrimidine Chemical compound C=1C=CC(Cl)=CC=1C(C)OC(N=1)=NC=CC=1N1CCNCC1 PFKJMESILVYLQS-UHFFFAOYSA-N 0.000 description 1
- AIFVACPLVHXPME-UHFFFAOYSA-N 2-[1-(3-fluorophenyl)ethoxy]-4-methyl-6-piperazin-1-ylpyrimidine Chemical compound C=1C=CC(F)=CC=1C(C)OC(N=1)=NC(C)=CC=1N1CCNCC1 AIFVACPLVHXPME-UHFFFAOYSA-N 0.000 description 1
- UXACGMNLBLFPQV-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)ethoxy]-6-piperazin-1-ylpyrazine Chemical group ClC1=CC=CC(CCOC=2N=C(C=NC=2)N2CCNCC2)=C1 UXACGMNLBLFPQV-UHFFFAOYSA-N 0.000 description 1
- XFVFOSGWIJHHPO-CQSZACIVSA-N 2-[3-[2-[3-[(2r)-2-methylpiperazin-1-yl]pyrazin-2-yl]oxyethoxy]pyridin-2-yl]oxyethanamine Chemical compound C[C@@H]1CNCCN1C1=NC=CN=C1OCCOC1=CC=CN=C1OCCN XFVFOSGWIJHHPO-CQSZACIVSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- PXMNBTNIDJTYFM-NSHDSACASA-N 2-[[4-[(2s)-2-aminopropyl]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-6-yl]oxy]ethanol Chemical compound C12=CC=C(OCCO)C=C2C(C[C@@H](N)C)=C2N1CCC2 PXMNBTNIDJTYFM-NSHDSACASA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ZJRJISIATULYIL-UHFFFAOYSA-N 2-chloro-3-[(3-chlorophenyl)methoxy]-5-piperazin-1-ylpyrazine Chemical group ClC1=CC=CC(COC=2C(=NC=C(N=2)N2CCNCC2)Cl)=C1 ZJRJISIATULYIL-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- HCGFLVDMFDHYJD-UHFFFAOYSA-N 2-piperazin-1-ylpyrazine Chemical group C1CNCCN1C1=CN=CC=N1 HCGFLVDMFDHYJD-UHFFFAOYSA-N 0.000 description 1
- XCQFQGFHDMRIJB-UHFFFAOYSA-N 3-[(3-chlorophenyl)methoxy]-1-oxido-5-piperazin-1-ylpyrazin-1-ium Chemical compound N=1C(N2CCNCC2)=C[N+]([O-])=CC=1OCC1=CC=CC(Cl)=C1 XCQFQGFHDMRIJB-UHFFFAOYSA-N 0.000 description 1
- CVXKDULHYNQXGA-UHFFFAOYSA-N 3-[(3-chlorophenyl)methoxy]-2-fluoro-5-piperazin-1-ylpyrazine Chemical group FC1=NC=C(N2CCNCC2)N=C1OCC1=CC=CC(Cl)=C1 CVXKDULHYNQXGA-UHFFFAOYSA-N 0.000 description 1
- LEXVVQNKFIXJOP-UHFFFAOYSA-N 3-[(6-piperazin-1-ylpyrazin-2-yl)oxymethyl]aniline Chemical compound NC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1 LEXVVQNKFIXJOP-UHFFFAOYSA-N 0.000 description 1
- UXJDGSAVALXBTN-UHFFFAOYSA-N 3-[(6-piperazin-1-ylpyrazin-2-yl)oxymethyl]benzonitrile Chemical compound N#CC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1 UXJDGSAVALXBTN-UHFFFAOYSA-N 0.000 description 1
- CPVBWHBWLRSCHV-UHFFFAOYSA-N 4-[(2-methoxyphenyl)methoxy]-2-piperazin-1-ylpyrimidine Chemical compound COC1=CC=CC=C1COC1=CC=NC(N2CCNCC2)=N1 CPVBWHBWLRSCHV-UHFFFAOYSA-N 0.000 description 1
- CXOHCQFVEIUPEW-UHFFFAOYSA-N 4-piperazin-1-yl-2-(pyridin-2-ylmethoxy)pyrimidine Chemical compound C=1C=CC=NC=1COC(N=1)=NC=CC=1N1CCNCC1 CXOHCQFVEIUPEW-UHFFFAOYSA-N 0.000 description 1
- 229940116892 5 Hydroxytryptamine 2B receptor antagonist Drugs 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 102000006969 5-HT2B Serotonin Receptor Human genes 0.000 description 1
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- 101710138092 5-hydroxytryptamine receptor 2B Proteins 0.000 description 1
- 102100024956 5-hydroxytryptamine receptor 2B Human genes 0.000 description 1
- PMZMPGDSRIYTDF-UHFFFAOYSA-N 6-bromo-8-(2,4-dichlorophenyl)-2,3,4,4a,5,9b-hexahydro-1h-pyrido[4,3-b]indole Chemical compound ClC1=CC(Cl)=CC=C1C(C=C1Br)=CC2=C1NC1CCNCC12 PMZMPGDSRIYTDF-UHFFFAOYSA-N 0.000 description 1
- DYCDNKQNLQYZCD-UHFFFAOYSA-N 8,9-dichloro-2,3,4,4a,5,6-hexahydro-1h-pyrazino[1,2-a]quinoxaline Chemical compound N1CC2CNCCN2C2=C1C=C(Cl)C(Cl)=C2 DYCDNKQNLQYZCD-UHFFFAOYSA-N 0.000 description 1
- OGVIBOYOTLEICI-UHFFFAOYSA-N 8-(2,4-dichlorophenyl)-2,3,4,4a,5,9b-hexahydro-1h-pyrido[4,3-b]indole Chemical compound ClC1=CC(Cl)=CC=C1C1=CC=C(NC2C3CNCC2)C3=C1 OGVIBOYOTLEICI-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010004954 Birth trauma Diseases 0.000 description 1
- KSHLDNKSBYMDQG-UHFFFAOYSA-N C1NCCC(N2CCOC(=C32)N=2)C1C3=CC=2C1=CC=CC=C1 Chemical compound C1NCCC(N2CCOC(=C32)N=2)C1C3=CC=2C1=CC=CC=C1 KSHLDNKSBYMDQG-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- DYUXHGLOHHQSDJ-UHFFFAOYSA-N ClC1=CC(Cl)=CC=C1C1=CC(C2C(CCNC2)N2CCO3)=C2C3=N1 Chemical compound ClC1=CC(Cl)=CC=C1C1=CC(C2C(CCNC2)N2CCO3)=C2C3=N1 DYUXHGLOHHQSDJ-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 101000617550 Dictyostelium discoideum Presenilin-A Proteins 0.000 description 1
- 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- SCRZCUNDEHVBDQ-MRXNPFEDSA-N FC1=CC(OCCC)=CC(F)=C1C[C@@]1(C)N(C(O)=O)CCNC1 Chemical compound FC1=CC(OCCC)=CC(F)=C1C[C@@]1(C)N(C(O)=O)CCNC1 SCRZCUNDEHVBDQ-MRXNPFEDSA-N 0.000 description 1
- RXSKHZZJWNOXAI-UHFFFAOYSA-N FC1=CC=CC(F)=C1C1=CC(C2C(CCNC2)N2CCO3)=C2C3=N1 Chemical compound FC1=CC=CC(F)=C1C1=CC(C2C(CCNC2)N2CCO3)=C2C3=N1 RXSKHZZJWNOXAI-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000017911 HTR1A Human genes 0.000 description 1
- 101150015707 HTR1A gene Proteins 0.000 description 1
- 101150104779 HTR2A gene Proteins 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 description 1
- GFDFZTFQPIBNSQ-LDIYZUBKSA-N Homoormosanine Natural products N12[C@H]3[C@H](C[C@H]4[C@@H]5N(C[C@@]3([C@@H]3N(C1)CCCC3)C4)CCCC5)CCC2 GFDFZTFQPIBNSQ-LDIYZUBKSA-N 0.000 description 1
- 101150039275 Htr1f gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- OTJOPJYJJAZRSC-UHFFFAOYSA-N N-[(3-chlorophenyl)methyl]-2-piperazin-1-ylpyrimidin-4-amine hydrochloride Chemical compound Cl.Clc1cccc(CNc2ccnc(n2)N2CCNCC2)c1 OTJOPJYJJAZRSC-UHFFFAOYSA-N 0.000 description 1
- YUBVDAKUPGXFTL-UHFFFAOYSA-N N-[(3-chlorophenyl)methyl]-4-piperazin-1-ylpyrimidin-2-amine hydrochloride Chemical compound Cl.Clc1cccc(CNc2nccc(n2)N2CCNCC2)c1 YUBVDAKUPGXFTL-UHFFFAOYSA-N 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- AZLIYAXCQAFORZ-CYBMUJFWSA-N [4-(cyclopropylmethoxy)-2,6-difluorophenyl]methyl (2r)-2-ethylpiperazine-1-carboxylate Chemical compound CC[C@@H]1CNCCN1C(=O)OCC(C(=C1)F)=C(F)C=C1OCC1CC1 AZLIYAXCQAFORZ-CYBMUJFWSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000037020 contractile activity Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 101150075901 htr2 gene Proteins 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- GFDFZTFQPIBNSQ-WSBLSWJJSA-N jamine Chemical compound C([C@H]([C@H]12)C3)CCN2CN2CCCC[C@@H]2[C@]21CN1CCCC[C@@H]1[C@H]3C2 GFDFZTFQPIBNSQ-WSBLSWJJSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 230000036453 micturition reflex Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- IDFANOPDMXWIOP-UHFFFAOYSA-N n,n-dimethylpentan-1-amine Chemical compound CCCCCN(C)C IDFANOPDMXWIOP-UHFFFAOYSA-N 0.000 description 1
- NXTBEUAMGPLPKC-UHFFFAOYSA-N n-[(2,3-difluorophenyl)methyl]-6-piperazin-1-ylpyrazin-2-amine Chemical compound FC1=CC=CC(CNC=2N=C(C=NC=2)N2CCNCC2)=C1F NXTBEUAMGPLPKC-UHFFFAOYSA-N 0.000 description 1
- OQZJOFWBSRLCML-UHFFFAOYSA-N n-[(2,5-difluorophenyl)methyl]-6-piperazin-1-ylpyrazin-2-amine Chemical compound FC1=CC=C(F)C(CNC=2N=C(C=NC=2)N2CCNCC2)=C1 OQZJOFWBSRLCML-UHFFFAOYSA-N 0.000 description 1
- KKGJUZHECNHLDO-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-6-piperazin-1-ylpyrazin-2-amine Chemical compound ClC1=CC=CC(CNC=2N=C(C=NC=2)N2CCNCC2)=C1 KKGJUZHECNHLDO-UHFFFAOYSA-N 0.000 description 1
- MEDBUZAILMLXCO-OAHLLOKOSA-N n-methyl-2-[3-[2-[3-[(2r)-2-methylpiperazin-1-yl]pyrazin-2-yl]oxyethoxy]pyridin-2-yl]oxyethanamine Chemical compound CNCCOC1=NC=CC=C1OCCOC1=NC=CN=C1N1[C@H](C)CNCC1 MEDBUZAILMLXCO-OAHLLOKOSA-N 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- QGRQJMXAQYGAKK-UHFFFAOYSA-N ver-3323 Chemical compound C1=C(Br)C=C2N(CC(N)C)CCC2=C1 QGRQJMXAQYGAKK-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0309533 | 2003-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200507158B true ZA200507158B (en) | 2006-11-29 |
Family
ID=33397006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200507158A ZA200507158B (en) | 2003-04-25 | 2005-09-06 | Treatment of incontinence with 5HTC2 agonists |
Country Status (13)
Country | Link |
---|---|
EP (2) | EP2277513A3 (ja) |
JP (2) | JP2006524679A (ja) |
KR (3) | KR20070108921A (ja) |
CN (1) | CN1780612B (ja) |
AU (2) | AU2004233745B2 (ja) |
BR (1) | BRPI0409730A (ja) |
CA (2) | CA2523379C (ja) |
CL (1) | CL2004000826A1 (ja) |
MX (1) | MXPA05011410A (ja) |
MY (1) | MY142857A (ja) |
TW (1) | TW200426142A (ja) |
WO (1) | WO2004096196A2 (ja) |
ZA (1) | ZA200507158B (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006022420A1 (ja) | 2004-08-25 | 2006-03-02 | Takeda Pharmaceutical Company Limited | 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法 |
TW200716106A (en) * | 2005-04-24 | 2007-05-01 | Wyeth Corp | Methods for modulating bladder function |
US20080234280A1 (en) * | 2005-08-01 | 2008-09-25 | Mcmurray Gordon | Use of Mc4 Receptor Agonist Compounds |
WO2007132841A1 (ja) | 2006-05-16 | 2007-11-22 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物およびその用途 |
EP2039695A4 (en) | 2006-07-11 | 2010-09-15 | Takeda Pharmaceutical | BICYCLIC HETEROCYLIC COMPOUND AND ITS USE |
WO2008108445A1 (ja) | 2007-03-07 | 2008-09-12 | Takeda Pharmaceutical Company Limited | ベンゾオキサゼピン誘導体およびその用途 |
US8329687B2 (en) | 2007-11-15 | 2012-12-11 | Takeda Pharmaceutical Company Limited | Pyridooxazepine derivative and use thereof |
US20100266504A1 (en) | 2007-11-15 | 2010-10-21 | Takahiro Matsumoto | Condensed pyridine derivative and use thereof |
WO2009063993A1 (ja) * | 2007-11-15 | 2009-05-22 | Takeda Pharmaceutical Company Limited | 縮合ピリジン誘導体およびその用途 |
SG176696A1 (en) | 2009-06-15 | 2012-01-30 | Takeda Pharmaceutical | Pyrazinooxazepine derivatives |
JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
WO2012002583A1 (en) * | 2010-07-02 | 2012-01-05 | Vanderbilt University | Method for treating schizophrenia and related diseases with a combination therapy |
JP6198715B2 (ja) | 2012-03-06 | 2017-09-20 | 武田薬品工業株式会社 | 三環性化合物 |
WO2019131902A1 (ja) | 2017-12-27 | 2019-07-04 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
CA2044854A1 (en) | 1990-07-19 | 1992-01-20 | Hong-I Chen | Method for preventing or treating urinary incontinence |
EP0572863A1 (de) | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | ZNS Pyrazinoindole |
TW334423B (en) | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
TW270114B (ja) | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
IT1282705B1 (it) | 1996-02-28 | 1998-03-31 | Recordati Chem Pharm | Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria |
WO1998030548A1 (fr) | 1997-01-13 | 1998-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | AGONISTES DU RECEPTEUR 5-HT2c ET DERIVES D'AMINOALKYLINDAZOLE |
WO1998033504A1 (en) * | 1997-02-03 | 1998-08-06 | Akzo Nobel N.V. | Treatment of urinary incontinence |
ES2208812T3 (es) | 1997-02-25 | 2004-06-16 | Akzo Nobel N.V. | Derivados de azetidina y de pirrolidina. |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
AU727654B2 (en) | 1997-06-13 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Tricyclic pyrazole derivative |
NZ506465A (en) * | 1998-02-26 | 2003-08-29 | Akzo Nobel Nv | Derivatives of azetidine and pyrrolidine |
AU4037699A (en) | 1998-05-08 | 1999-11-29 | Akzo Nobel N.V. | Novel aryl-hydro naphthalenal kanamines |
GB9819032D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds IV |
GB9819019D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
GB9819035D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Res Ltd | Chemical compounds VII |
GB9819020D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds III |
GB9819033D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds VI |
GB9820767D0 (en) | 1998-09-23 | 1998-11-18 | Cerebrus Ltd | Chemical compounds VIII |
WO2000028993A1 (en) | 1998-11-19 | 2000-05-25 | Nortran Pharmaceuticals, Inc. | Serotonin ligands as pro-erectile compounds |
KR20010108025A (ko) | 1998-12-17 | 2001-12-07 | 이곤 이 버그 | 5HT2C 효능제인2,3,4,4a-테트라하이드로-1H-피라지노(1,2-a)퀴녹살린-5(6H)온 유도체 |
EP1149085A1 (en) | 1999-01-27 | 2001-10-31 | Eli Lilly And Company | Aminoalkylbenzofurans as serotonin (5-ht(2c)) agonists |
WO2000069437A1 (en) | 1999-05-18 | 2000-11-23 | Synaptic Pharmaceutical Corporation | Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder |
SE9901884D0 (sv) * | 1999-05-21 | 1999-05-21 | Pharmacia & Upjohn Ab | Novel compounds their use and preparation |
BR0010783A (pt) * | 1999-05-21 | 2002-04-09 | Biovitrum Ab | Novos compostos, seu uso e preparação |
US6465467B1 (en) * | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
BR0012086A (pt) | 1999-06-15 | 2002-04-02 | Bristol Myers Squibb Pharma Co | Compostos derivados de gama-carbolinas fundidas com heterociclos substituìdos, composição farmacêutica e usos dos compostos |
US6399826B1 (en) * | 1999-08-11 | 2002-06-04 | Sepracor Inc. | Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain |
GB9918962D0 (en) | 1999-08-11 | 1999-10-13 | Cerebrus Ltd | Chemical compounds xxii |
GB9918965D0 (en) | 1999-08-11 | 1999-10-13 | Cerebrus Ltd | Chemical compounds xxi |
US20030004207A1 (en) | 1999-11-29 | 2003-01-02 | Douglas A. Craig | Use of compounds which activate a 5-ht receptor to treat urinary incontinence |
EP1132389A1 (en) | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
CA2402472A1 (en) | 2000-03-14 | 2001-10-04 | Michael Dalton Ennis | 2,3,4,5-tetrahydro-1h-¬1,4|diazepino¬1,7a|indole compounds |
WO2001083487A1 (fr) | 2000-04-28 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de froindazole |
SE0002754D0 (sv) * | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New pharmaceutical combination formulation and method of treatment with the combination |
SE0004245D0 (sv) | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
ATE470662T1 (de) * | 2000-11-20 | 2010-06-15 | Biovitrum Ab Publ | Piperazinylpyrazinverbindungen als agonisten oder antagonisten am serotonin-5ht-2-rezeptor |
EP1337518B1 (en) * | 2000-11-20 | 2009-06-17 | Biovitrum AB (publ) | Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor |
US6498184B2 (en) * | 2000-12-05 | 2002-12-24 | Akzo Nobel N.V. | Serotonergic compound for a method of treatment of hot flushes in post-menopausal women |
GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
PL366627A1 (en) | 2000-12-20 | 2005-02-07 | Bristol-Myers Squibb Company | Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists |
PL366233A1 (en) | 2000-12-20 | 2005-01-24 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
AU2002228007B2 (en) | 2000-12-27 | 2007-06-21 | F. Hoffmann-La Roche Ag | Indole derivatives and their use as 5-HT2b and 5-HT2c receptor ligands |
GB0106177D0 (en) | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
WO2002074746A1 (fr) | 2001-03-16 | 2002-09-26 | Yamanouchi Pharmaceutical Co., Ltd. | Derives de benzazepine |
US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
CA2451606A1 (en) | 2001-07-05 | 2003-01-16 | Pharmacia & Upjohn Company | (hetero) aryl substituted benzofurans as 5-ht ligands |
WO2003014125A1 (en) | 2001-08-06 | 2003-02-20 | Pharmacia & Upjohn Company | Therapeutically useful tetracyclic ligands |
BR0211608A (pt) | 2001-08-08 | 2006-04-04 | Upjohn Co | 1h-pirido[4,3-b]indóis terapêuticos |
CA2460126A1 (en) | 2001-09-21 | 2003-03-27 | Pharmacia & Upjohn Company | Tricyclic indole derivatives as 5-ht ligands |
BR0213417A (pt) * | 2001-10-18 | 2004-11-03 | Upjohn Co | Compostos e composições de tetraciclicazaindóis e indolinas tendo atividade de 5-ht e seus usos |
AU2002367323A1 (en) | 2001-12-28 | 2003-07-24 | Bayer Pharmaceuticals Corporation | Benzothieno (3,2- |
JP2005517681A (ja) | 2001-12-28 | 2005-06-16 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 5−ht2c受容体と関連する疾患における使用のための4−スルフィド/スルホキシド/スルホニル−1h−ピラゾリル誘導体化合物 |
EP1465871A1 (en) | 2001-12-28 | 2004-10-13 | Bayer Corporation | Pyrazole derivatives for use in diseases associated with the 5-ht2c receptor |
AU2002360819A1 (en) | 2001-12-28 | 2003-07-24 | Bayer Corporation | Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor |
AU2003243089B2 (en) | 2002-06-19 | 2010-01-07 | Biovitrum Ab (Publ) | Novel compounds, their use and preparation |
-
2004
- 2004-04-16 CL CL200400826A patent/CL2004000826A1/es unknown
- 2004-04-21 KR KR1020077022222A patent/KR20070108921A/ko not_active Application Discontinuation
- 2004-04-21 CA CA2523379A patent/CA2523379C/en not_active Expired - Fee Related
- 2004-04-21 CA CA002670067A patent/CA2670067A1/en not_active Abandoned
- 2004-04-21 WO PCT/IB2004/001437 patent/WO2004096196A2/en active Application Filing
- 2004-04-21 EP EP10177541A patent/EP2277513A3/en not_active Withdrawn
- 2004-04-21 CN CN2004800111992A patent/CN1780612B/zh not_active Expired - Fee Related
- 2004-04-21 KR KR1020057020223A patent/KR20060006063A/ko not_active Application Discontinuation
- 2004-04-21 JP JP2006506590A patent/JP2006524679A/ja active Pending
- 2004-04-21 BR BRPI0409730-0A patent/BRPI0409730A/pt not_active IP Right Cessation
- 2004-04-21 AU AU2004233745A patent/AU2004233745B2/en not_active Ceased
- 2004-04-21 KR KR1020107019252A patent/KR20100103726A/ko not_active Application Discontinuation
- 2004-04-21 MX MXPA05011410A patent/MXPA05011410A/es unknown
- 2004-04-21 EP EP04728610A patent/EP1620081A2/en not_active Withdrawn
- 2004-04-23 MY MYPI20041485A patent/MY142857A/en unknown
- 2004-04-23 TW TW093111427A patent/TW200426142A/zh unknown
-
2005
- 2005-09-06 ZA ZA200507158A patent/ZA200507158B/en unknown
-
2010
- 2010-07-20 AU AU2010203093A patent/AU2010203093A1/en not_active Abandoned
- 2010-11-08 JP JP2010249395A patent/JP2011064695A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1620081A2 (en) | 2006-02-01 |
MY142857A (en) | 2011-01-14 |
CA2523379A1 (en) | 2004-11-11 |
AU2010203093A1 (en) | 2010-08-12 |
KR20100103726A (ko) | 2010-09-27 |
CN1780612B (zh) | 2010-12-01 |
EP2277513A3 (en) | 2011-09-07 |
KR20060006063A (ko) | 2006-01-18 |
CN1780612A (zh) | 2006-05-31 |
WO2004096196A2 (en) | 2004-11-11 |
JP2011064695A (ja) | 2011-03-31 |
MXPA05011410A (es) | 2005-12-12 |
BRPI0409730A (pt) | 2006-05-09 |
JP2006524679A (ja) | 2006-11-02 |
TW200426142A (en) | 2004-12-01 |
CA2670067A1 (en) | 2004-11-11 |
CA2523379C (en) | 2010-06-22 |
WO2004096196A3 (en) | 2005-03-10 |
KR20070108921A (ko) | 2007-11-13 |
CL2004000826A1 (es) | 2005-03-04 |
AU2004233745B2 (en) | 2010-03-25 |
EP2277513A2 (en) | 2011-01-26 |
AU2004233745A1 (en) | 2004-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200507158B (en) | Treatment of incontinence with 5HTC2 agonists | |
US20110152272A1 (en) | Treatment Of Incontinence | |
US6821975B1 (en) | Beta-carboline drug products | |
CN104302295B (zh) | 用tor 激酶抑制剂治疗癌症 | |
AU773666B2 (en) | Beta-carboline drug products | |
US20040235856A1 (en) | Treatment of incontinence | |
JP2008501776A (ja) | 肥満に関連し、かつメタボリックシンドロームに関連する状態の治療としてのホスホジエステラーゼ10の阻害 | |
CN108992446A (zh) | 用tor激酶抑制剂治疗癌症 | |
RU2746601C2 (ru) | Орвепитант для лечения хронического кашля | |
US20060270655A1 (en) | Combination therapy for treating obesity or maintaining weight loss | |
US9907795B2 (en) | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents | |
Mennini et al. | Mechanism of action of anxiolytic drugs | |
JP2008546777A (ja) | 癌の治療のための4−アニリノ−3−キノリンカルボニトリル | |
Ram et al. | Medicinal chemistry of drugs with active metabolites (N-, O-, and S-desalkylation and some specific oxidative alterations) | |
US20040224907A1 (en) | Compositions and methods for reversal of drug resistance |